Med.IQ

About

The first healthtech knowledge company in Latin America. We connect, create, and disseminate content with the purpose of driving change and fostering new future possibilities for doctors and patients. We enable educational solutions.

Website

https://https://portalmediq.com/us/

Content by Med.IQ

Med.IQ

24 jul, 2025

Osimertinib Combined with Chemotherapy Demonstrates Significant Overall Survival Benefit in Advanced EGFR-Mutated Lung Cancer

The combination of osimertinib with chemotherapy (pemetrexed plus either cisplatin or carboplatin) demonstrated a significant overall survival (OS) benefit in patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), according to final results from the Phase 3 FLAURA2 study released by AstraZeneca in July 2025.The data show that the combination reduced the risk of death by 20% compared to osimertinib monotherapy, with a median OS of 44.3

Oncology

2min

Med.IQ

11 jun, 2025

Digital Remote Monitoring in People with Multiple Sclerosis

IntroductionAn article published in Frontiers in Immunology explores how digital technologies, combined with artificial intelligence (AI) and big data, are revolutionizing the remote monitoring of people with Multiple Sclerosis (MS), a chronic neurodegenerative disease affecting more than 2.8 million people worldwide.MS impairs sensorimotor and cognitive functions, significantly impacting patients’ quality of life. Traditional clinical monitoring, typic

Neurology

5min

Med.IQ

11 jun, 2025

FDA Approves First Blood Test for Alzheimer’s Diagnosis

On May 16, 2025, the U.S. Food and Drug Administration (FDA) approved the first blood test designed to aid in the diagnosis of Alzheimer’s disease. The Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, developed by Fujirebio Diagnostics, measures the ratio of two plasma proteins — pTau217 and β-amyloid 1-42 — associated with the presence of amyloid plaques in the brain, one of the key biomarkers of the disease.Intended for adults aged 55 and older who present with signs and symptom

Neurology

3min